1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Drugs In Development, 2022, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 3, 4, 4, 2 and 11 respectively.
Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Macular Edema - Overview
- Macular Edema - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Macular Edema - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Macular Edema - Companies Involved in Therapeutics Development
- 3SBio Inc
- Aerie Pharmaceuticals Inc
- AsclepiX Therapeutics Inc
- Celon Pharma SA
- Clearside BioMedical Inc
- Clonz Biotech Pvt Ltd
- Coherus BioSciences Inc
- F. Hoffmann-La Roche Ltd
- Huadong Medicine Co Ltd
- Luye Pharma Group Ltd
- Mabion SA
- Novartis AG
- Oculis SA
- PharmAbcine Inc
- Polus Inc
- Prestige BioPharma Ltd
- Profarma
- Ripple therapeutics Corp
- Shilpa Medicare Ltd
- Sustained Nano Systems LLC
- Taiwan Liposome Co Ltd
- Targeted Therapy Technologies LLC
- Tarsius Pharma Ltd
- Tiantai Yinkang Biological Medicine Co Ltd
- Macular Edema - Drug Profiles
- 601A anti-VEGF Ab - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- aflibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- AXT-107 - Drug Profile
- Product Description
- Mechanism Of Action
- celecoxib - Drug Profile
- Product Description
- Mechanism Of Action
- dexamethasone acetate - Drug Profile
- Product Description
- Mechanism Of Action
- dexamethasone sodium phosphate SR 1 - Drug Profile
- Product Description
- Mechanism Of Action
- dexamethasone SR - Drug Profile
- Product Description
- Mechanism Of Action
- dexamethasone XR - Drug Profile
- Product Description
- Mechanism Of Action
- faricimab - Drug Profile
- Product Description
- Mechanism Of Action
- IBI-304 - Drug Profile
- Product Description
- Mechanism Of Action
- MHU-650 - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibodies to Inhibit VEGF for Age Related Macular Degeneration and Macular Edema - Drug Profile
- Product Description
- Mechanism Of Action
- ranibizumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- ranibizumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- ranibizumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- ranibizumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- ranibizumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- ranibizumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- ranibizumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- ranibizumab SR - Drug Profile
- Product Description
- Mechanism Of Action
- triamcinolone acetonide - Drug Profile
- Product Description
- Mechanism Of Action
- TRS-02 - Drug Profile
- Product Description
- Mechanism Of Action
- Macular Edema - Dormant Projects
- Macular Edema - Discontinued Products
- Macular Edema - Product Development Milestones
- Featured News & Press Releases
- Sep 19, 2022: Coherus to launch CIMERLI (ranibizumab-eqrn) in the United States on October 3, 2022
- Aug 02, 2022: FDA approves Coherus' CIMERLI (ranibizumab-eqrn) as the first and only interchangeable biosimilar to Lucentis for all five indications, with 12 months of interchangeability exclusivity
- Jul 07, 2022: Clearside Biomedical suprachoroidal delivery technology to be featured at upcoming ASRS and OIS Medical Meetings
- Jul 06, 2022: Bausch + Lomb announces scientific data on XIPERE (Triamcinolone Acetonide Injectable Suspension) to be presented during the American Society of Retina Specialists Annual Scientific Meeting
- May 05, 2022: Clearside Biomedical poster presentation on XIPERE at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology
- Mar 28, 2022: Bausch + Lomb and Clearside Biomedical announce the U.S. commercial launch of XIPERE (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal use for the treatment of macular edema associated with uveitis
- Nov 23, 2021: Arctic Vision starts dosing with ARVN001 in macular oedema trial
- Nov 16, 2021: Clearside Biomedical features FDA-approved XIPERE in multiple presentations at the American Academy of Ophthalmology 2021 and American Uveitis Society Meetings
- Oct 26, 2021: Sansheng Guojian's anti-VEGF monoclonal antibody 601A (ophthalmology) CRVO project phase IIa clinical trial was completed and subjects were enrolled
- Oct 25, 2021: FDA approves Bausch + Lomb and Clearside’s macular oedema treatment
- Oct 06, 2021: Aerie Pharmaceuticals announces presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists
- Jun 02, 2021: Bausch Health and Clearside Biomedical announce U.S. FDA filing acceptance for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension)
- May 10, 2021: Clearside Biomedical announces poster presentation on XIPERE at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting
- May 03, 2021: Clearside Biomedical announces resubmission of new drug application for XIPERE for treatment of macular edema associated with uveitis
- Feb 08, 2021: Clearside Biomedical presented data on XIPERE at the 44th Virtual Annual Macula Society Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Macular Edema, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Macular Edema - Dormant Projects, 2022
- Macular Edema - Discontinued Products, 2022
- Number of Products under Development for Macular Edema, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- Aerie Pharmaceuticals Inc
- AsclepiX Therapeutics Inc
- Celon Pharma SA
- Clearside BioMedical Inc
- Clonz Biotech Pvt Ltd
- Coherus BioSciences Inc
- F. Hoffmann-La Roche Ltd
- Huadong Medicine Co Ltd
- Luye Pharma Group Ltd
- Mabion SA
- Novartis AG
- Oculis SA
- PharmAbcine Inc
- Polus Inc
- Prestige BioPharma Ltd
- Profarma
- Ripple therapeutics Corp
- Shilpa Medicare Ltd
- Sustained Nano Systems LLC
- Taiwan Liposome Co Ltd
- Targeted Therapy Technologies LLC
- Tarsius Pharma Ltd
- Tiantai Yinkang Biological Medicine Co Ltd
